Answers are grounded in this paper and cite their sources.
// Kavin Sugumar 1 , Andrew Alabd 2 , Andre Alabd 3 , Jonathan J. Hue 1 , Josh Lyons 1 , Sherri Fields 4 , Zev Wainberg 4 , Lei Zheng 5 , Brianna Coogle 6 , Anup Kasi 6 , Nicholas Grewal 7 , Hedy L. Kindler 7 , Jason Starr 8 , Ashwin R. Sama 9 and Jordan M. Winter 1 1 Department of Surgery, University Hospitals Seidman Cancer Center, Cleveland, OH 44106, USA 2 Department of Medicine, Cooper University Healthcare, Camden, NJ 08103, USA 3 Department of Urology, University of Indiana, Indianapolis, IN 46227, USA 4 Department of Medicine, UCLA/Santa Monica Cancer Center, CA 90404, USA 5 Department of Medicine, Johns Hopkins University, Baltimore, MD 21218, USA 6 Department of Medicine, University of Kansas Medical Center, Kansas City, KS 66103, USA 7 Department of Medicine, University of Chicago, Chicago, IL 60637, USA 8 Department of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA 9 Department of Medicine, Jefferson Medical Oncology Associates, Philadelphia, PA 19107, USA Correspondence to: Jordan M. Winter, email: jordan.winter@UHHospitals.org Keywords: pancreatic adenocarcinoma; immunotherapy; exceptional responders; microsatellite instability; survival Received: December 18, 2024 Accepted: May 17, 2025 Published: June 10, 2025 Copyright: © 2025 Sugumar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Introduction: Immunotherapy has emerged as a standard treatment option for multiple solid tumors. However, most patients with pancreatic cancer (PC) do not derive a significant benefit. Identification and analyses of exceptional responders could eventually offer hints as to why PC is resistant to immunotherapy. Methods: Oncologists from cancer centers in the United States were contacted to identify patients with PC who responded to immunotherapy. Exceptional responders were defined as those having either partial (PR) or complete response (CR) based on Response Evaluation Criteria in Solid Tumors, or biochemical response (CA 19-9 levels) after starting immunotherapy. Patients receiving concurrent chemotherapy were excluded. Results: 14 patients met inclusion criteria. Immunotherapy drugs included checkpoint inhibitors and macrophage inhibitors. Eight patients (42%) were MSI (microsatellite instability)-high. Radiologically, 82% had PR. Four patients (28%) had marked reduction in CA 19-9. The median progression-free survival was 12 months from the start of immunotherapy. Median survival was not reached. The 1- and 2-year survival probabilities were 80%, 70% respectively. Conclusion: Majority of clinical trials evaluating immunotherapy in PC have yielded disappointing response rates compared to other solid tumors. Our case series adds to published data from early-phase trials supporting the promise of immunotherapy in some patients with PC.
No takes yet. Share an insight, caveat, or question.
Sugumar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: